BACKGROUND: Various factors influence the development and rate of fibrosis progression in chronic hepatitis C virus (HCV) infection. OBJECTIVES: To examine factors associated with fibrosis in a longterm outcomes study of Alaska Native/American Indian persons who underwent liver biopsy, and to examine the rate of fibrosis progression in persons with subsequent biopsies. METHODS: A cross-sectional analysis of the demographic, inflammatory and viral characteristics of persons undergoing liver biopsy compared individuals with early (Ishak fibrosis score of lower than 3) with those with advanced (Ishak score of 3 or greater) fibrosis. Persons who underwent two or more biopsies were analyzed for factors associated with fibrosis progression. RESULTS: Of 253 HCV RNA-positive persons who underwent at least one liver biopsy, 76 (30%) had advanced fibrosis. On multivariate analysis, a Knodell histological activity index score of 10 to 14 and an alpha-fetoprotein level of 8 ng/mL or higher were found to be independent predictors of advanced liver fibrosis (P<0.0001 for each). When surrogate markers of liver inflammation (alanine aminotransferase, aspartate aminotransferase/alanine aminotransferase ratio and alpha-fetoprotein) were removed from the model, type 2 diabetes mellitus (P=0.001), steatosis (P=0.03) and duration of HCV infection by 10-year intervals (P=0.02) were associated with advanced fibrosis. Among 52 persons who underwent two or more biopsies a mean of 6.2 years apart, the mean Ishak fibrosis score increased between biopsies (P=0.002), with progression associated with older age at initial biopsy and HCV risk factors. CONCLUSIONS: The presence of type 2 diabetes mellitus, steatosis and duration of HCV infection were independent predictors of advanced fibrosis in the present cohort, with significant fibrosis progression demonstrated in persons who underwent serial biopsies.
BACKGROUND: Various factors influence the development and rate of fibrosis progression in chronic hepatitis C virus (HCV) infection. OBJECTIVES: To examine factors associated with fibrosis in a longterm outcomes study of Alaska Native/American Indian persons who underwent liver biopsy, and to examine the rate of fibrosis progression in persons with subsequent biopsies. METHODS: A cross-sectional analysis of the demographic, inflammatory and viral characteristics of persons undergoing liver biopsy compared individuals with early (Ishak fibrosis score of lower than 3) with those with advanced (Ishak score of 3 or greater) fibrosis. Persons who underwent two or more biopsies were analyzed for factors associated with fibrosis progression. RESULTS: Of 253 HCV RNA-positive persons who underwent at least one liver biopsy, 76 (30%) had advanced fibrosis. On multivariate analysis, a Knodell histological activity index score of 10 to 14 and an alpha-fetoprotein level of 8 ng/mL or higher were found to be independent predictors of advanced liver fibrosis (P<0.0001 for each). When surrogate markers of liver inflammation (alanine aminotransferase, aspartate aminotransferase/alanine aminotransferase ratio and alpha-fetoprotein) were removed from the model, type 2 diabetes mellitus (P=0.001), steatosis (P=0.03) and duration of HCV infection by 10-year intervals (P=0.02) were associated with advanced fibrosis. Among 52 persons who underwent two or more biopsies a mean of 6.2 years apart, the mean Ishak fibrosis score increased between biopsies (P=0.002), with progression associated with older age at initial biopsy and HCV risk factors. CONCLUSIONS: The presence of type 2 diabetes mellitus, steatosis and duration of HCV infection were independent predictors of advanced fibrosis in the present cohort, with significant fibrosis progression demonstrated in persons who underwent serial biopsies.
Authors: Ke-Qin Hu; Namgyal L Kyulo; Eric Esrailian; Kevin Thompson; Resa Chase; Donald J Hillebrand; Bruce A Runyon Journal: J Hepatol Date: 2004-01 Impact factor: 25.083
Authors: M G Bruce; D Bruden; B J McMahon; C Christensen; C Homan; D Sullivan; H Deubner; J Williams; S E Livingston; D Gretch Journal: J Viral Hepat Date: 2008-03 Impact factor: 3.728
Authors: Brian J McMahon; Thomas W Hennessy; Carol Christensen; Dana Bruden; Daniel G Sullivan; Chriss Homan; Heike Deubner; Michael G Bruce; Stephen Livingston; James Williams; David R Gretch Journal: Hepatology Date: 2004-02 Impact factor: 17.425
Authors: Alexander Monto; Keyur Patel; Alan Bostrom; Stephen Pianko; Paul Pockros; John G McHutchison; Teresa L Wright Journal: Hepatology Date: 2004-03 Impact factor: 17.425
Authors: Mark Danta; Gregory J Dore; Lisa Hennessy; Yueming Li; Chris R Vickers; Hugh Harley; Meng Ngu; William Reed; Paul V Desmond; William Sievert; Geoff C Farrell; John M Kaldor; Robert G Batey Journal: Med J Aust Date: 2002-09-02 Impact factor: 7.738
Authors: Brian J McMahon; Dana Bruden; Lisa Townshend-Bulson; Brenna Simons; Phillip Spradling; Stephen Livingston; James Gove; Annette Hewitt; Julia Plotnik; Chriss Homan; Hannah Espera; Susan Negus; Mary Snowball; Youssef Barbour; Michael Bruce; Prabhu Gounder Journal: Clin Gastroenterol Hepatol Date: 2016-10-17 Impact factor: 11.382
Authors: Stuart C Gordon; Lois E Lamerato; Loralee B Rupp; Scott D Holmberg; Anne C Moorman; Philip R Spradling; Eyasu Teshale; Fujie Xu; Joseph A Boscarino; Vinutha Vijayadeva; Mark A Schmidt; Nancy Oja-Tebbe; Mei Lu Journal: Am J Gastroenterol Date: 2015-07-28 Impact factor: 10.864
Authors: Anna Mania; Mariusz Kaczmarek; Paweł Kemnitz; Iwona Mozer-Lisewska; Jan Sikora; Magdalena Figlerowicz; Aldona Woźniak; Katarzyna Mazur-Melewska; Wojciech Służewski; Jan Żeromski Journal: Inflammation Date: 2013-10 Impact factor: 4.092